Journal article

Effect of Sodium Benzoate vs Placebo Among Individuals With Early Psychosis A Randomized Clinical Trial

James G Scott, Andrea Baker, Carmen CW Lim, Sharon Foley, Frances Dark, Anne Gordon, David Ward, Drew Richardson, George Bruxner, K Martin Beckmann, Sean Hatherill, Stephen Stathis, Krystal Dixon, Alexander E Ryan, Brett C McWhinney, Jacobus PJ Ungerer, Michael Berk, Olivia M Dean, Sukanta Saha, John McGrath

JAMA Network Open | AMER MEDICAL ASSOC | Published : 2020


Importance: There is evidence that sodium benzoate (BZ) may be an effective adjunctive treatment for schizophrenia. The clinical efficacy of BZ has been investigated in chronic schizophrenia; however, the efficacy of this agent has not been studied in individuals with early psychosis. Objective: To examine the clinical efficacy of the adjunctive use of BZ for symptoms in people with early psychosis. Design, Setting, and Participants: Using a placebo-controlled double-masked parallel-group design, this randomized clinical trial was conducted from August 2015 to July 2018. Participants aged between 15 and 45 years experiencing early psychosis were enrolled from 5 major clinical sites in Queens..

View full abstract

University of Melbourne Researchers


Awarded by John Cade Fellowship from the NHMRC

Awarded by NHMRC

Funding Acknowledgements

This project was supported by a John Cade Fellowship (No. APP1056929 to DrMcGrath) from the NHMRC. The project was supported by the Queensland Centre for Mental Health Research, which receives funding from the Queensland Health Department. Dr Scott is supported by an NHMRC Practitioner Fellowship (No. 1105807). Dr Berk is supported by an NHMRC Senior Principal Research Fellowship (Nos. 1059660 and 1156072). Dr Dean is a R.D. Wright NHMRC Biomedical Career Development Fellow (No. APP1145634).